Effectiveness and safety of the direct oral anticoagulant in acute distal deep vein thrombosis: From the prospective multicenter observational study, J’xactly, in Japan

• Published in: Phlebology 2023-02, Vol.38 (1), p.4-15
• Main Authors: Mo, Makoto, Fukuda, Ikuo, Nakamura, Mashio, Yamada, Norikazu, Takayama, Morimasa, Maeda, Hideaki, Yamashita, Takeshi, Ikeda, Takanori, Yamazaki, Tsutomu, Okumura, Yasuo, Hirayama, Atsushi
• Format: Article
• Language: English
• ISSN: 0268-3555; 1758-1125
• DOI: 10.1177/02683555221141310

Objectives We assessed the effectiveness and safety of rivaroxaban in patients with isolated distal deep vein thrombosis (IDDVT). Methods Symptomatic venous thromboembolism (VTE) and major bleeding were assessed. Results Of 1016 patients with acute symptomatic/asymptomatic DVT and/or pulmonary embolism treated with rivaroxaban, 288 had IDDVT and 294 had proximal DVT (pDVT). The IDDVT group had fewer patients on the higher rivaroxaban dose (30 mg/day) (42.7% vs. 66.0%) and a shorter treatment duration (135.5 vs 369.5 days) than the pDVT group. VTE recurrence occurred in 14 and 11 patients with IDDVT and pDVT, respectively (2.89% vs. 2.29% per patient-year; p = 0.534). Major bleeding was less frequent in the IDDVT group (1.55% vs. 4.53% per patient-year; p = 0.044). Comparable effectiveness and safety were observed with 15 and 30 mg/day rivaroxaban in the IDDVT group. Conclusions Short-term, low-dose rivaroxaban seems safe and effective for IDDVT treatment.